[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-376663-105":59,"doc-detail-376663-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","antibody-based-therapeutics-for-the-treatment-of-renal-cell-carcinoma-challenges-and-opportunities","Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma - Challenges and Opportunities","","Renal cell carcinoma (RCC) is one of the most common cancers, and metastatic disease remains difficult to cure despite major progress. Over the last decade, immunotherapy has moved to the forefront, yet problems persist in patient selection, treatment sequencing, and both intrinsic and acquired resistance. Antibody-based therapeutics targeting molecules such as CD70, CA9, and ENPP3 are under clinical evaluation, but most have not improved outcomes in advanced RCC. This review synthesizes emerging antibody trials and explains challenges required to enable effective, tolerable therapeutic antibodies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antibody-based-therapeutics-for-the-treatment-of-renal-cell-carcinoma-challenges-and-opportunities/376663/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antibody-based-therapeutics-for-the-treatment-of-renal-cell-carcinoma-challenges-and-opportunities/376663.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is metastatic renal cell carcinoma still challenging despite newer therapies?","Question",{"text":113,"@type":114},"Large fractions of patients develop treatment resistance and progression, and unresolved issues include patient selection and treatment sequencing as well as intrinsic and acquired resistance.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What antibody-based therapeutics are being explored for RCC?",{"text":118,"@type":114},"Emerging clinical-trial options include antibodies targeting CD70, CA9, and ENPP3 for patients resistant or refractory to current immunotherapies.",{"name":120,"@type":111,"acceptedAnswer":121},"What does the review focus on regarding antibody-based treatments?",{"text":122,"@type":114},"It summarizes the evolving RCC therapeutic landscape, describes recent clinical trials of antibody-based therapeutics, and outlines key challenges needed to design more effective and tolerable antibodies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},376663,1790837511,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities  \nAhmed M. Mahmoud1,, Reza Nabavizadeh1, Rodrigo Rodrigues Pessoa1, Ishita Garg2, Jacob Orme3, Brian A. Costello1,3, John Cheville4, Fabrice Lucien*, 1,  \n1Department of Urology, Mayo Clinic, Rochester, MN, USA 2Department of Immunology, Mayo Clinic, Rochester, MN, USA 3Department of Oncology, Mayo Clinic, Rochester, MN, USA 4Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA  \n*Corresponding author: Fabrice Lucien, PhD, Mayo Clinic, Guggenheim 4-97, 200 1st Street SW, Rochester, MN 55901, USA.  \nEmail: [lucien-matteoni.fabrice@mayo.edu](lucien-matteoni.fabrice@mayo.edu)  \nAbstract  \nRenal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC.  \nKey words: renal cell carcinoma; metastatic RCC; antibody-based therapies; immunotherapy; clinical trials; emerging drugs.  \nImplications for Practice  \nIn this review, the reader will receive a thorough overview of the various antibody-based therapeutic options for patients with advanced renal cell carcinoma. As the molecular biology and cytogenetics of RCC being explored more, various targeted medications have been investigated to improve patient outcomes; additionally, they provide physicians the chance to tailor therapies for specific patients. In our review, we highlighted the limitations of previous and most recently conducted clinical trials on antibody-based therapeutics and the approaches put forth to overcome those issues.  \nIntroduction  \nRenal cell carcinoma (RCC) is the most frequent subtype of kidney cancer with an estimated 400 000 occurrences globally.1 Overall, the lifetime risk for developing kidney cancer in men is approximately 1 in 46 (2.02%), and for women is approximately 1 in 80 (1.03%) .2 Nearly 30% of patients present with de novo metastatic disease and almost 30% of those with initial localized disease will eventually develop  \nmetastases after surgical resection of the primary tumor.3  \nOver the past 2 decades, there have been significant changes in the management and treatment of metastatic RCC.4 First-generation immunotherapy with interleukinsor interferon which was previously standard of care is now fallen out of favor due to subpar results and high toxicity.5,6 Subsequently, the prognosis for both progression-free survival  \n(PFS) and overall survival (OS) was significantly improved by the introduction of tyrosine kinase inhibitors (TKI), primarily VEGF receptor inhibitors.7 Later the immune checkpoint inhibitors (ICI) emerged which alone or in combination with TKIs have led to better oncologic outcomes.8,9 Because RCCis considered as an immu","cbCaiqL6qNQAPt42","https://ap.wps.com/l/cbCaiqL6qNQAPt42","pdf",7174243,"English","# Abstract\n# Implications for Practice\n# Introduction\n# Materials and Methods\n# The Evolving Therapeutic Landscape of Metastatic RCC\n## 2005-2015: The “VEGF Inhibitors” Era","[{\"question\":\"Why is metastatic renal cell carcinoma still challenging despite newer therapies?\",\"answer\":\"Large fractions of patients develop treatment resistance and progression, and unresolved issues include patient selection and treatment sequencing as well as intrinsic and acquired resistance.\"},{\"question\":\"What antibody-based therapeutics are being explored for RCC?\",\"answer\":\"Emerging clinical-trial options include antibodies targeting CD70, CA9, and ENPP3 for patients resistant or refractory to current immunotherapies.\"},{\"question\":\"What does the review focus on regarding antibody-based treatments?\",\"answer\":\"It summarizes the evolving RCC therapeutic landscape, describes recent clinical trials of antibody-based therapeutics, and outlines key challenges needed to design more effective and tolerable antibodies.\"}]","Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma - Challenges and Opportunities | PDF",1790220511]